Adrenal Crisis Mimicking COVID-19 Encephalopathy in a Teenager with Craniopharyngioma

Tzu-Chien Chien 1, Mu-Ming Chien 1, Tsai-Ling Liu 1, Hsi Chang 1,2,3, Min-Lan Tsai 1,2,3, Sung-Hui Tseng 2,4,5,6, Wan-Ling Ho 1,2,3, Yi-Yu Su 1, Hsiu-Chen Lin 1,3, Jen-Her Lu 1,3, Chia-Yau Chang 1,2,3, Kevin Li-Chun Hsieh 2,7,8,9, Tai-Tong Wong 2,9,10,11,12, James S. Miser 2,13,14 and Yen-Lin Liu 1,2,3,9,*

1 Department of Pediatrics, Taipei Medical University Hospital, Taipei 110, Taiwan
2 Pediatric Brain Tumor Program, Taipei Cancer Center, Taipei Medical University, Taipei 110, Taiwan
3 Department of Pediatrics, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan
4 Department of Physical Medicine and Rehabilitation, Taipei Medical University Hospital, Taipei 110, Taiwan
5 Department of Physical Medicine and Rehabilitation, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan
6 Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan
7 Department of Medical Imaging, Taipei Medical University Hospital, Taipei 110, Taiwan
8 Department of Radiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan
9 TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei 110, Taiwan
10 Division of Pediatric Neuropsychiatry, Department of Neuropsychiatry, Taipei Medical University Hospital, Taipei 110, Taiwan
11 Neuroscience Research Center, Taipei Medical University Hospital, Taipei 110, Taiwan
12 Taipei Neuroscience Institute, Taipei Medical University, Taipei 110, Taiwan
13 Department of Pediatrics, City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA
14 Cancer Center, Taipei Medical University Hospital, Taipei 110, Taiwan
* Correspondence: ylliu@tmu.edu.tw; Tel.: +886-2-2737-2181 (ext. 3715); Fax: +886-2-6639-7181

Abstract: There is an increasing number of reported cases with neurological manifestations of COVID-19 in children. Symptoms include headache, general malaise, ageusia, seizure and alterations in consciousness. The differential diagnosis includes several potentially lethal conditions including encephalopathy, encephalitis, intracranial hemorrhage, thrombosis and adrenal crisis. We report the case of a 17-year-old boy with a positive antigen test of COVID-19 who presented with fever for one day, altered mental status and seizure, subsequently diagnosed with adrenal insufficiency. He had a history of panhypopituitarism secondary to a suprasellar craniopharyngioma treated with surgical resection; he was treated with regular hormone replacement therapy. After prompt administration of intravenous hydrocortisone, his mental status returned to normal within four hours. He recovered without neurologic complications. Adrenal insufficiency can present with neurological manifestations mimicking COVID-19 encephalopathy. Prompt recognition and treatment of adrenal insufficiency, especially in patients with brain tumors, Addison’s disease or those recently treated with corticosteroids, can rapidly improve the clinical condition and prevent long-term consequences.

Keywords: COVID-19; SARS-CoV-2; craniopharyngioma; panhypopituitarism; adrenal insufficiency; seizure

1. Introduction

In March 2020, the World Health Organization officially declared COVID-19 as a pandemic, which has affected a great number of children worldwide [1]. It predominantly presents with respiratory symptoms; however, neurologic manifestations in children have been increasingly reported [2]. Some children have neurologic manifestations as the only presentation of COVID-19 [3]. Most of the neurologic symptoms, occurring in 20% of cases, are non-specific, including headache and ageusia. Importantly, approximately 1%...
of pediatric cases develop severe neurological complications including encephalopathy, seizures, Guillain–Barré syndrome and intracranial hemorrhage [4,5]. In hospitalized children with acute COVID-19, risk factors of neurological manifestations included older age and preexisting neurological, cardiovascular or metabolic conditions; children with neurological manifestations are more likely to be admitted to the intensive care unit and with longer hospital stays [6].

Adrenal insufficiency, a potentially life-threatening condition, typically presents with nonspecific symptoms including fatigue, nausea, and vomiting, as well as signs of mineralocorticoid deficiency including hypotension, dehydration, and/or electrolyte abnormalities [7]. Adrenal insufficiency can sometimes present with neurologic symptoms including weakness, lethargy, headache and even seizure and coma [8].

Here, we report the occurrence of adrenal insufficiency in a patient with COVID-19 and a history of suprasellar craniopharyngioma presenting with altered mental status and seizure mimicking COVID-19 encephalopathy.

2. Case Presentation

A 17-year-old teenage boy presented with high fever and disturbance of consciousness. He had past history of a suprasellar craniopharyngioma, which had been completely resected 3 years prior to presentation (Figure 1). He had had diabetes insipidus and panhypopituitarism since the onset of craniopharyngioma that had persisted postoperatively, for which he received regular follow-up and hormone replacement therapy with oral cortisone acetate (25 mg twice daily), desmopressin, and levothyroxine. He was unvaccinated against COVID-19.

On the morning of presentation, the patient suffered from intermittent high fever. He only took cortisone acetate 25 mg in the morning and was too sick to take the evening dose. A rapid antigen test of COVID-19 was positive at home. A few hours later, he became drowsy and soon developed generalized tonic–clonic seizures for more than 10 min. Upon arrival in the Emergency Department, his vital signs were blood pressure, 103/58 mmHg; heart rate, 108 beats per minute; respiratory rate, 18 times per minute; body temperature, 39 °C. He had obesity based on the Ministry of Health and Welfare of Taiwan; his weight was 78 kg and height was 163 cm, with a body mass index (BMI) of 29.4 kg/m² (96.5 percentile or a Z-score of 1.76, based on Centers for Disease Control and Prevention published BMI reference standards). Physical exam showed normal breath sounds, rapid heart rate, warm extremities and capillary refill time of less than 2 s. Neurological exam showed drowsiness with a Glasgow Coma Scale of E3V3M5, symmetric pupil size (2.5 mm) with light reflex, no Kernig or Brudzinski sign and no drop foot.

COVID-19 quantitative reverse-transcriptase polymerase chain reaction (QRT-PCR) showed positive with a threshold cycle (Ct) value of 14.2, a high viral load in acute phase. Laboratory data revealed increased levels of C-reactive protein (2 mg/dL), procalcitonin (0.5 ng/mL) and interleukin-6 (IL-6; 145.3 pg/mL) (Table 1). Computed tomography showed no space-occupying lesions, no cerebral edema and no intracranial hemorrhage (Figure 2). Lumbar puncture was attempted to collect cerebral spinal fluid but failed. After initial multidisciplinary consultations, adrenal crisis was the primary diagnosis, with differential diagnosis including acute encephalitis of COVID-19, multi-system inflammatory syndrome in children (MIS-C), and concomitant herpetic encephalitis. An immediate dose of 100 mg of hydrocortisone was loaded intravenously in the ED, followed by 50 mg every six hours (100 mg/m²/day). Intravenous acyclovir was also given empirically. The patient was admitted to the Intensive Care Unit for close observation. After a multidisciplinary discussion, a 3-day-course of Remdesivir, 200 mg on the first day and 100 mg on the next two days, was administered. His consciousness and mental status returned normal at 4 h after administration of hydrocortisone. Acyclovir was discontinued because of the rapid response to hydrocortisone and the very low likelihood of herpes simplex virus infection. We gradually tapered the hydrocortisone dose and changed to oral...
cortisone acetate at the previous physiological dose. The patient was discharged with no neurological sequelae on the fifth day after diagnosis of COVID-19.

Table 1. Laboratory data at presentation.

| Test          | Our Case   | Normal Range        |
|---------------|------------|---------------------|
| White blood cell | 6700/uL   | 4000–11,000/uL      |
| Hemoglobin    | 12.8 g/dL  | 13–17 g/dL          |
| Platelet      | 211 × 10^3/uL | 130–400 × 10^3/uL  |
| Neutrophil    | 59.3%      | 40–74%              |
| Lymphocyte    | 21.1%      | 19–48%              |
| Monocyte      | 17.6%      | 2–12%               |

Figure 1. Neuroimaging of the patient’s craniopharyngioma before and after surgical treatment. (a) At diagnosis: Magnetic resonance imaging (MRI) at the age of 13 years showed a round, well-circumscribed, vividly enhanced, suprasellar tumor measured 27 × 28 × 29 mm in size. (b) After surgery: MRI on the 7th postoperative day showed a gross total resection. (c) Most recent follow-up: MRI at 3 months before onset of COVID-19 showed no signs of tumor progression. All images were T1-weighed magnetic resonance imaging with contrast enhancement.
Table 1. Cont.

| Test                        | Our Case | Normal Range          |
|-----------------------------|----------|-----------------------|
| Eosinophils                 | 1.5%     | 0–7%                  |
| Basophils                   | 0.5%     | 0–2%                  |
| Prothrombin time            | 15.9 s   | 11–15 s               |
| aPTT                        | 53.9 s   | 32–45 s               |
| Fibrinogen                  | 350 mg/dL| 200–400 mg/dL         |
| D-dimer                     | 0.73 ug/mL| <0.5 ug/mL        |
| FDP                         | <4 ug/mL | <5 ug/mL              |
| C-reactive protein          | 2.01 mg/dL| <0.5 mg/dL       |
| Procalcitonin               | 0.51 ng/mL| <0.046 ng/mL    |
| Interleukin-6               | 145.3 pg/mL| <7 pg/mL       |
| Blood urea nitrogen         | 13 mg/dL | 6–20 mg/dL            |
| Creatinine                  | 0.8 mg/dL| 0.7–1.2 mg/dL        |
| AST                         | 88 U/L   | <40 U/L               |
| ALT                         | 49 U/L   | <41 U/L               |
| Direct bilirubin            | 0.4 mg/dL| 0–0.3 mg/dL           |
| Total bilirubin             | 0.9 mg/dL| 0–1.2 mg/dL           |
| Creatinine kinase           | 44 U/L   | 20–200 U/L            |
| Creatinine kinase-MB        | 12 U/L   | <25 U/L               |
| Troponin T                  | 0.006 ng/mL| 0–0.014 ng/mL          |
| Glucose                     | 149 mg/dL| 80–140 mg/dL          |
| Ammonia                     | 28 ug/dL | 27–102 ug/dL          |
| Lactate                     | 6.1 mg/dL| 4.5–19.8 mg/dL        |
| Na                          | 133 mEq/L| 136–145 mEq/L         |
| K                           | 3.4 mEq/L| 3.5–5.1 mEq/L         |
| Ca                          | 8.6 mg/dL| 8.6–10.2 mg/dL        |
| Mg                          | 1.9 mg/dL| 1.6–2.6 mg/dL         |
| P                           | 4.7 mg/dL| 2.7–4.5 mg/dL         |
| Cortisol (PM) *             | 0.05 ug/dL| 7–10 AM: 6.2–19.4 ug/dL |
| ACTH *                      | 10.3 pg/mL| 4–8 PM: 2.3–11.9 ug/dL |
| T3 *                        | 152 ng/dL| 7.9–47.1 pg/mL        |
| Free T4 *                   | 1.7 ng/dL| 80–200 ng/dL          |
| TSH *                       | <0.01 ulU/mL| 0.27–4.2 ulU/mL       |

*The endocrine function test results were available at 12 h after initial evaluation. Abbreviations: ACTH: adrenocorticotropic hormone; aPTT: activated partial thromboplastin time; AST: aspartate aminotransferase; ALT: alanine transaminase; TSH: thyroid stimulating hormone.

![Figure 2](image_url). Two different cuts of brain CT revealed no space-occupying lesions, no cerebral edema and no intracranial hemorrhage. (a) Level of the midbrain. (b) Level of the pons.
3. Discussion

3.1. COVID-19 in Children with Cancer and Brain Tumor

Our case is an adolescent brain tumor survivor who experienced adrenal insufficiency related to acute COVID-19 infection. Most of the children with malignancies have a mild disease of COVID-19 [9,10]. However, pediatric oncology patients are prone to suffer from worse clinical conditions and more likely to require ICU support when compared to non-oncology patients [11]. Among brain tumors, unlike other oncology diseases, there seems to be no significant difference in mortality from COVID-19. It may be explained by less myelosuppressive brain tumor therapy [12]. Rossella et al. reported a 9-year-old girl with suprasellar non-germinomatous germ cell tumor and hypothalamic-pituitary failure. She was accidentally found to be infected with COVID-19 when screened before admission for autologous stem-cell transplantation (ASCT). She was asymptomatic during the course, and she received ASCT one month later [13].

3.2. Adrenal Insufficiency in COVID-19 Patients

Adrenal insufficiency is a potentially lethal condition characterized by impaired synthesis and release of adrenocortical hormones. Our patient presented with fever, seizure, and conscious change and was finally diagnosed with adrenal insufficiency according to his clinical response to corticosteroids. Flokas et al. reported a pediatric post-COVID-19 adrenal insufficiency, presenting as MIS-C [14]. An adolescent presented with altered mental status four days after being COVID-19 positive and was eventually diagnosed with Addison’s disease, which was presumed to be triggered by COVID-19 [15]. These cases illustrate that we should keep adrenal insufficiency in mind when approaching a change in consciousness in patients with COVID-19, especially in patients with predisposing factors including a brain tumor, Addison’s disease or recent use of corticosteroids.

3.3. Neurological Manifestation of COVID-19 and the Current Management

Evidence of COVID-19 invasion to the central neural system was found in some cases [16,17]. Sejal et al. described a case of COVID-19-related encephalitis in an adolescent, who also had seizures and altered mental status. After a 10-day-course of Remdesivir, his neurologic symptoms improved on the fourth day [18]. Acute fulminant cerebral edema (AFCE) is proposed to be a phenotype of encephalitis in children [19]. Seizure and status epilepticus are two important significant factors of AFCE [20]. Siddharth et al. described a previously healthy 8-year-old girl, presenting with newly onset seizures and encephalopathy, and rapidly progressed to acute fulminant cerebral edema (AFCE) after COVID-19 infection. Despite receiving dexamethasone, intravenous immunoglobulin, Remdesivir, and anakinra, she eventually developed tonsillar herniation and expired [21]. Multisystem inflammation syndrome in children (MIS-C) is an uncommon complication following COVID-19 infection. MIS-C has a similar clinical picture with Kawasaki disease and is potentially life-threatening. A higher incidence of neurological involvement was observed in children diagnosed with MIS-C related to COVID-19 in up to 34% cases [22]. Our case had symptoms that overlapped with MIS-C. He had three system involvements: neurologic, gastrointestinal, and hematologic. Acute phase reactants, including IL-6, CRP, and procalcitonin, were elevated, although he didn’t fully meet the criteria of MIS-C at the time of admission. Adrenal insufficiency was confirmed on the next day with clinical improvements that made the diagnosis of MIS-C unlikely.

3.4. Long COVID

Long COVID is a term to describe persisting symptoms after infection with COVID-19. Among children and adolescents, the incidence of long COVID varied widely from 4 to 66% [23]. A Swedish case series reported five pediatric patients of long COVID. Common symptoms include fatigue, dyspnea, chest pain, cognitive impairment, and depression, lasting up to 6-8 months after infected with COVID-19 [24]. Older age, ICU admission, and muscle soreness on admission are significantly related to pediatric long COVID [25]. Long-
term follow-up in our case is required. We arranged outpatient department of rehabilitation for this case to detect any signs of long COVID and start an early rehabilitation program.

3.5. Limitations

In summary, we report a rare case with a brain tumor experiencing COVID-19 infection and adrenal insufficiency. After prompt hydrocortisone administration, he had a rapid recovery of neurological symptoms. We reinforced to the patient and family about the need to double the dose of cortisone acetate during major illnesses.

Our limitation is that we lack CSF analysis and magnetic resonance imaging (MRI) so we can’t fully rule out encephalitis. As the patient’s consciousness improved rapidly after the administration of steroids and his neurologic examination revealed no remarkable findings, we deferred MRI arrangement and repeating the lumbar puncture. Had there been no clinical improvement, we would have performed a lumbar puncture again and arranged an MRI.

4. Conclusions

In a patient with COVID-19 presenting with altered mental status, adrenal insufficiency should always be considered in the differential diagnosis, because adrenal insufficiency can present with neurologic manifestations mimicking COVID-19 encephalopathy. Prompt recognition and treatment of adrenal insufficiency can rapidly improve the clinical condition and prevent long-term consequences. Though our case had no neurologic sequelae one week later, long-term follow-up is needed to evaluate the possibility of long COVID syndrome.

Author Contributions: Conceptualization, Y.-L.L., H.C., W.-L.H. and S.-H.T.; writing—original draft preparation, T.-C.C., J.S.M. and Y.-L.L.; writing—review and editing M.-M.C., T.-L.L., H.C., M.-L.T., S.-H.T., W.-L.H., Y.-S., H.-C.L., J.-H.L., C.-Y.C., K.L.-C.H. and T.-W.; funding acquisition, Y.-L.L. All authors have read and agreed to the published version of the manuscript.

Funding: The study was funded, in part, by the National Science and Technology Council, Taiwan, Grant Number MOST-109-2314-B-038-072.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Joint Institutional Review Board of Taipei Medical University No. N20220600.

Informed Consent Statement: Patient consent was waived due to epidemic outbreak concern.

Data Availability Statement: Not applicable.

Acknowledgments: This work was supported in part by the “TMU Research Center of Cancer Translational Medicine” from The Featured Areas Research Center Program within the framework of the Higher Education Sprout Project by the Ministry of Education (MOE) in Taiwan. The authors thank Yu-Han Chung, MS at the Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan for her coordination of the Pediatric Brain Tumor Program.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Dawood, F.S.; Porucznik, C.A.; Veguilla, V.; Stanford, J.B.; Duque, J.; Rolifes, M.A.; Dixon, A.; Third, P.; Hacker, E.; Castro, M.J.E.; et al. Incidence Rates, Household Infection Risk, and Clinical Characteristics of SARS-CoV-2 Infection Among Children and Adults in Utah and New York City. New York. JAMA Pediatr. 2022, 176, 59–67. [CrossRef] [PubMed]

2. Abdel-Mannan, O.; Eyre, M.; Löbel, U.; Bamford, A.; Eltze, C.; Hameed, B.; Hemingway, C.; Hacohen, Y. Neurologic and Radiographic Findings Associated With COVID-19 Infection in Children. JAMA Neurol. 2020, 77, 1440–1445. [CrossRef] [PubMed]

3. Aljomah, L.; Almedlej, S.; Baarmah, D.; Altwaijri, W.; Akrumayyan, A.; Alrifai, M.T.; Almugbil, M.; Alshalaan, M. Pediatrics COVID-19 and neurological manifestations: Single tertiary centre experience. eNeurologicalSci 2021, 24, 100355. [CrossRef] [PubMed]

4. Gürkas, E.; Dünya, B.; Köken, Ö.Y.; Demirdağ, T.; Yılmaz, D.; Özyürek, H.; Kurt, A. Neurologic manifestations of COVID 19 in children: Prospective study in a single center. Ann. Indian Acad. Neurol. 2021, 24, 891–895. [CrossRef] [PubMed]

5. Panda, P.K.; Sharawat, I.K.; Panda, P.; Natarajan, V.; Bhakat, R.; Dawman, L. Neurological Complications of SARS-CoV-2 Infection in Children: A Systematic Review and Meta-Analysis. J. Trop. Pediatr. 2021, 67, fmaa070. [CrossRef] [PubMed]
6. Fink, E.L.; Robertson, C.L.; Wainwright, M.S.; Roa, J.D.; Lovett, M.E.; Stulce, C.; Yacoub, M.; Potera, R.M.; Zivick, E.; Holloway, A.; et al. Prevalence and Risk Factors of Neurologic Manifestations in Hospitalized Children Diagnosed with Acute SARS-CoV-2 or MIS-C. Pediatr. Neurol. 2022, 128, 33–44. [CrossRef]

7. Husebye, E.S.; Pearce, S.H.; Krone, N.P.; Kämpe, O. Adrenal insufficiency. Lancet 2021, 397, 613–629. [CrossRef]

8. Patti, G.; Guzzetti, C.; Di Iorgi, N.; Allegri, A.M.; Napoli, F.; Loche, S.; Maghnie, M. Central adrenal insufficiency in children and adolescents. Best Pract. Res. Clin. Endocrinol. Metab. 2018, 32, 425–444. [CrossRef]

9. Sundberg, E.; Georgantzi, K.; Langenskiöld, C.; Król, L.; Nilsson, F.; Vogt, H.; Palle, J.; Ek, T.; Nilsson, A. Low numbers of COVID-19 in Swedish pediatric oncology patients during the first pandemic year despite an open society. Pediatr. Blood Cancer 2022, e29750. [CrossRef]

10. Bisogno, G.; Provenzi, M.; Zama, D.; Tondo, A.; Meazza, D.; Galaverna, F.; Compagno, F.; Carraro, F.; De Santis, R.; et al. Clinical Characteristics and Outcome of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Italian Pediatric Oncology Patients: A Study from the Infectious Diseases Working Group of the Associazione Italiana di Oncologia e Ematologia Pediatrica. J. Pediatr. Infect. Dis. Soc. 2020, 9, 530–534. [CrossRef]

11. Madhusoodhan, P.P.; Pierro, J.; Musante, J.; Kothari, P.; Tal, A.; Hogan, L.; Sharma, A.; et al. Characterization of COVID-19 disease in pediatric oncology patients: The New York-New Jersey regional experience. Pediatr. Blood Cancer 2021, 68, e28843. [CrossRef]

12. Ronsley, R.; Bouffet, E. COVID-19 in pediatric cancer: Where are the brain tumors? Neuro Oncol. 2021, 23, 1977–1979. [PubMed]

13. Gaudino, R.; Orlandi, V.; Cavarzere, P.; Chinello, M.; Antoniazi, F.; Cesaro, S.; Piacentini, G. Case Report: SARS-CoV-2 Infection in a Child with Suprasellar Tumor and Hypothalamic-Pituitary Failure. Front. Endocrinol. 2021, 12, 596654. [CrossRef] [PubMed]

14. Flokas, M.E.; Bustamante, V.H.; Kanakatti Shankar, R. New onset Primary Adrenal Insufficiency and Autoimmune Hypothyroidism in a Pediatric Patient presenting with MIS-C. Horm. Res. Paediatr. 2022. [CrossRef] [PubMed]

15. Bhavsar, S.M.; Agarwal, S.; Lewis, R.; Ganta, A.; Roshchina, Y.S.; Clouser, K.N.; Baer, A.Z.; Gliksman, F.; Piwoz, J.A. COVID-19 Infection Associated with Encephalitis in an Adolescent. Neurol. Clin. Pract. 2021, 11, e189–e192. [CrossRef]

16. Cheraghali, F.; Tahamtant, A.; Hosseini, S.A.; Ghareeb, M.H.; Moradi, A.; Razavi Nikoo, H.; Tabarraei, A. Case Report: Detection of SARS-CoV-2 From Cerebrospinal Fluid in a 34-Month-Old Child with Encephalitis. Front. Pediatr. 2021, 9, 565778. [CrossRef]

17. Salman, M.A.; Mallah, S.I.; Khalid, W.; Moran, L.R.; Abousedu, Y.A.; Jassim, G.A. Characteristics of Patients with SARS-CoV-2 Positive Cerebrospinal Fluid: A Systematic Review. Int. J. Gen. Med. 2021, 14, 10385–10395. [CrossRef]

18. Blavas, S.M.; Agarwal, S.; Lewis, R.; Ganta, A.; Roshchina, Y.S.; Clouser, K.N.; Baer, A.Z.; Gliksman, F.; Piwoz, J.A. COVID-19 Infection Associated with Encephalitis in an Adolescent. Neurol. Clin. Pract. 2021, 11, e189–e192. [CrossRef]

19. Krishnan, P.; Glenn, O.A.; Samuel, M.C.; Sheriff, H.; Foster-Barber, A.; Sejvar, J.J.; Roy-Burman, A.; Wadford, D.A.; Preas, C.P.; Tureen, J.H.; et al. Acute Fulminant Cerebral Edema: A Newly Recognized Phenotype in Children with Suspected Encephalitis. J. Pediatric Infect. Dis. Soc. 2021, 10, 289–294. [CrossRef]

20. Lan, S.-Y.; Lin, J.-J.; Hsia, S.-H.; Wang, H.-S.; Chiu, C.-H.; Lin, K.-L. Analysis of Fulminant Cerebral Edema in Acute Pediatric Encephalitis. Pediatr. Neonatol. 2021, 68, 402–407. [CrossRef]

21. Ninnan, S.; Thompson, P.; Gerhson, T.; Ford, N.; Mills, W.; Jewells, V.; Thorne, L.; Saunders, K.; Bouldin, T.; Smedberg, J.R.; et al. Fatal Pediatric COVID-19 Case with Seizures and Fulminant Cerebral Edema. Child Neurol. Open 2021, 8, 2329048x211022532. [CrossRef] [PubMed]

22. Chen, T.-H. Neurological involvement associated with COVID-19 infection in children. J. Neurol. Sci. 2020, 418, 117096. [CrossRef] [PubMed]

23. Zimmermann, P.; Pittet, L.F.; Curtis, N. How Common is Long COVID in Children and Adolescents? Pediatr. Infect. Dis. J. 2021, 40, e482–e487. [CrossRef]

24. Ludvigsson, J.F. Case report and systematic review suggest that children may experience similar long-term effects to adults after clinical COVID-19. Acta Paediatr. 2021, 110, 914–921. [CrossRef] [PubMed]

25. Asadi-Pooya, A.A.; Nemati, H.; Shahisavandi, M.; Akbari, A.; Emami, A.; Lotfi, M.; Rostamihosseinkhani, M.; Barzegar, Z.; Kabiri, M.; Zeraatpisheh, Z.; et al. Long COVID in children and adolescents. World J. Pediatr. 2021, 17, 495–499. [CrossRef] [PubMed]